Pluristem to Present at Omics Group's 2nd International Conference and Exhibition on Cell & Gene Therapy
October 23 2013 - 3:00AM
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading
developer of placenta-based cell therapies, announced today that
Pluristem's VP of Development, Ohad Karnieli PhD will present at
Omics Group's 2nd International Conference and Exhibition on Cell
& Gene Therapy in Orlando, Florida on October 25, 2013 at
12:50pm. Dr. Karnieli's presentation will focus on Pluristem's
approach on industrialized cell therapy manufacturing.
As previously announced, Pluristem's 3-dimensional cell
production is manufactured in its state-of-the-art 40,000 square
foot facility.
Omics Group's 2nd International Conference and Exhibition on
Cell & Gene Therapy 2013 is an event which brings together a
unique and international mix of leading universities and cell
therapy institutions making the congress a perfect platform to
share experience. It paves a way to gather visionaries through the
research talks and presentations and put forward many thought
provoking strategies in emerging cell & gene therapies.
The conference aims to serve as a catalyst for the advancement in
cell & gene therapies by connecting scientists within and
across disciplines at conferences held under a single roof that
create an environment conducive to information exchange, generation
of new ideas and acceleration of applications that benefit
society.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of
placenta-based cell therapies. The Company's patented PLX
(PLacental eXpanded) cells are a drug delivery platform that
releases a cocktail of therapeutic proteins in response to a host
of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental
technology and are an "off-the-shelf" product that requires no
tissue matching prior to administration.
Pluristem has a strong intellectual property position,
company-owned GMP certified manufacturing and research facilities,
strategic relationships with major research institutions and a
seasoned management team. For more information visit
www.pluristem.com, the content of which is not part of this press
release.
The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities
laws. These forward-looking statements and their implications are
based on the current expectations of the management of Pluristem
only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or
obstacles in launching and/or successfully completing our clinical
trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up
being more expensive than we anticipate; results in the laboratory
may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the
results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause
the actual results or performance of Pluristem to differ materially
from those contemplated in such forward-looking statements. Except
as otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.:
William Prather R.Ph., M.D. Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Jul 2023 to Jul 2024